Non-Hodgkin Lymphoma | Specialty

Dr. Burke on the Potential of Time-Limited BTK Inhibitor Therapy in B-Cell Malignancies

September 23rd 2020

John M. Burke, MD, discusses the potential benefits of time-limited therapy with BTK inhibitors in B-cell malignancies.

Dr. Hill on the Impact of Recent Approvals in Relapsed/Refractory DLBCL

September 23rd 2020

Brian T. Hill, MD, PhD, discusses the impact of recent regulatory approvals in relapsed/refractory diffuse large B-cell lymphoma.

AUTO3 CAR T-Cell Product Plus Pembrolizumab Shows Clinical Activity, Tolerability in Relapsed/Refractory DLBCL

September 23rd 2020

The investigational CAR T-cell product AUTO3 in combination with pembrolizumab was found to have a tolerable safety profile and elicit durable complete responses in patients with relapsed/refractory diffuse large B-cell lymphoma.

FDA Grants Priority Review to Crizotinib for Pediatric ALK+ Anaplastic Large Cell Lymphoma

September 23rd 2020

The FDA has granted a priority review to a supplemental new drug application for crizotinib in the treatment of pediatric patients with ALK-positive relapsed/refractory systemic anaplastic large cell lymphoma.

Ibrutinib Plus Short‐Course Fludarabine Elicits Encouraging CR Rates in Previously Untreated CLL

September 23rd 2020

Christopher Pleyer, MD, discusses the phase 2 trial examining fludarabine plus ibrutinib in CLL and SLL, the next steps for the research, and where future efforts should be focused.

Camrelizumab/Apatinib Combo Shows Preliminary Activity in Relapsed/Refractory Peripheral T-Cell Lymphoma

September 23rd 2020

The combination of the investigative PD-1 inhibitor camrelizumab plus the antiangiogenic agent apatinib led to early signals of clinical activity in patients with relapsed/refractory peripheral T-cell lymphoma, warranting further study.

FDA Approval Sought for Loncastuximab Tesirine for Relapsed/Refractory DLBCL

September 22nd 2020

A biologics license application has been submitted to the FDA for loncastuximab tesirine for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.

Dr. Zonder on the ZUMA-2 and ZUMA-5 Trials in MCL and iNHL

September 22nd 2020

Jeffrey Zonder, MD, discusses the ZUMA-2 trial in mantle cell lymphoma and the ZUMA-5 trial in indolent non-Hodgkin lymphoma.

Dr. Pagel on the Utility of CAR T-Cell Therapy in Relapsed/Refractory DLBCL

September 22nd 2020

John M. Pagel, MD, PhD, discusses the utility of CAR T-cell therapy in patients with relapsed/refractory diffuse large B-cell lymphoma.

Dr. Welslau on the Rationale for the REFLECT Trial With Rituximab Biosimilar

September 22nd 2020

Manfred Welslau, MD, discusses the rationale of the prospective REFLECT trial with the rituximab biosimilar SDZ-RTX in patients with diffuse large B-cell lymphoma.

Dr. Seymour on the Kinase Selectivity of BTK Inhibitors in CLL

September 22nd 2020

Erlene Seymour, MD, discusses the kinase selectivity of BTK inhibitors in chronic lymphocytic leukemia.

Expert Perspectives in the Evolving Treatment Landscape of Relapsed/Refractory Diffuse Large B-Cell Lymphoma

September 22nd 2020

Faculty debate the definitions of chemotherapy resistance, sensitivity, and refractoriness and discussed appropriate management strategies based on how patients would be classified in DLBCL.

Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma

September 22nd 2020

Recent trials of novel therapies and therapeutic combinations have introduced promising options for the management of patients with relapsed or refractory diffuse large B-cell lymphoma.

Bruton Tyrosine Kinase Inhibitors in B-Cell Lymphomas

September 22nd 2020

Bruton tyrosine kinase (BTK) inhibitors play an important role in the therapeutic spectrum of B-cell lymphomas.

Treatment of R/R DLBCL: Beyond CAR T Therapy

September 22nd 2020

Phase 2B SADAL Trial in R/R DLBCL

September 22nd 2020

RE-MIND Study in R/R DLBCL

September 22nd 2020

L-MIND Study in R/R DLBCL

September 22nd 2020

CAR T in Transplant-Eligible and Transplant-Ineligible DLBCL

September 22nd 2020

Standard of Care for Relapsed/Refractory DLBCL

September 22nd 2020